About this journal
Aims and scope
The Journal of Hepatocellular Carcinoma is an international, peer-reviewed, open access journal.
The journal provides the international community with a platform for the dissemination and study of clinical, translational, and basic research findings in this rapidly developing field. Primary liver tumors, primarily hepatocellular carcinoma (HCC), are the third leading cause of cancer death worldwide, with around 750,000 new cases annually, and around 700,000 deaths. While 80% occurs in the developing world, the incidence is beginning to decline due to hepatitis B vaccination and developments in food hygiene; conversely, there is an increasing incidence in the developed world, partly due to metabolic syndrome, obesity and diabetes.
The journal welcomes original research manuscripts, reviews, clinical trial reports, expert opinions and commentaries relating to all aspects of HCC, spanning from basic laboratory research through to clinical and translational research.
Meta-analyses will no longer be considered for publication.
Specific topics covered by the journal include:
- cell signalling pathways
- molecular tumor classification and prognostication
- new drugs and other therapies
- new radiology approaches
- epidemiology, surveillance, and prevention
- psychosocial aspects and quality of life issues
The journal will consider case reports only if they make a valuable and original contribution to the literature. Study protocols are not suitable unless at least pilot or baseline data are provided.
When considering submission of a paper utilizing publicly available data, authors should ensure that such studies add significantly to the body of knowledge and that they are validated using the authors' own data through replication in an original sample.
Journal metrics
Usage
- 63K annual downloads/views
Citation metrics
- 4.2 (2023) Impact Factor
- Q2 Impact Factor Best Quartile
- 4.1 (2023) 5 year IF
- 0.5 (2023) CiteScore (Scopus)
- 0.000 (2023) SNIP
- 0.000 (2023) SJR
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Editor-in-Chief:
Prof. Dr. Ahmed O Kaseb, Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, United States
Associate Editors-in-Chief:
Dr Rony Avritscher, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Laura A. Dawson, Department of Radiation Oncology, University of Toronto, Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Professor Khaled Elsayes, Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, United States
Dr David Gerber, Christian R. Holmes Professor of Surgery and Chair, Department of Surgery, University of Cincinnati, Cincinnati, OH, USA
Dr Mannal M. Hassan, Department of Epidemiology, University of Texas, MD Anderson Cancer Center, United States
Dr Ali Hosni, Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, Canada
Prof. Dr. Mohamed K Shaker, Tropical Medicine and Hepatology, Ain Shams University, Egypt
Dr Hop Tran Cao, Surgical Oncology, The University of Texas MD Anderson Cancer Center, United States
Professor Jorg Trojan, Department of Medicine, University Hospital Frankfurt, Germany
Professor Imam Waked, Department of Hepatology, National Liver Institute, Menofia University, Egypt
Editorial Board:
Professor Stephen J Beebe, Frank Reidy Research Center for Bioelectric, Old Dominion University, United States
Dr Srikanta Dash, Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, United States
Dr Aldo Dettino, Clinical Oncology, A. C. Camargo Cancer Center, Brazil
Dr Dan Duda, Department of Radiation Oncology, Harvard Medical School, Charlestown, MA, United States
Professor Mahmoud El Meteini, Professor, Faculty of Medicine - Ain Shams University, Egypt.
Professor Tamer Elbaz, Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Egypt
Dr Hesham Elghazaly, Oncology, Ain Shams University, Cairo, Egypt
Dr Catherine Frenette, Division of Gastroenterology and Hepatology, Scripps Green Hospital, United States
Professor Asmaa Gomaa, Hepatology, National Liver Institute, Menofia University, Egypt
Dr Heping Hu, Department of Hepatobilliary Medicine, Eastern Hepatobiliary Hospital, China Mainland (PRC)
Prof. Dr. Do Young Kim, Internal Medicine, Yonsei University College of Medicine, Korea, Republic of (South)
Professor Philippe Merle, Hepato-Gastroenterology and Digestive Oncology, and Epigenetics and Epigenomics of Hepatocellular Carcinoma (EpiHep), Centre of Research in Cancerology, Lyon University and Croix-Rousse Hospital, Lyon, France
Dr Ganesh Nagarajan, Consultant Surgeon Hepatobiliary Pancreatic, GI oncology & Liver Transplant, P D Hinduja Hospital, Mumbai, India
Prof. Dr. Ashraf Omar, Hepatology & Liver Transplantation, Consultant Founder of multidisciplinary HCC clinic Cairo University, President of Egyptian society of liver Cancer, Head of MENA NCCN Committee for HCC, Board member of Africa HepatoPancreatoBiliary Cancer Consortium (AHPBCC), Board member of Society of liver Diseases in Africa (SOLDA), Egypt
Dr Tushar Patel, Medicine, Mayo Clinic College of Medicine, Jacksonville, FL, USA
Dr Ramavath, Department of Pediatrics at the Washington University, USA
Professor Lorenza Rimassa, Associate Professor of Medical Oncology, Director of the Residency Program in Medical Oncology, Department of Biomedical Sciences, Humanitas University, Head of Hepatopancreatobiliary Oncology, Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy
Professor Rodolfo Sacco, Department of Gastroenterology, University of Foggia, Italy
Professor Toshihito Seki, Liver disease center, Kansai Medical University Medical Center, Japan
Professor Ming Shi, Department of Hepatobiliary Oncology, Sun Yat-sen University, China Mainland (PRC)
Prof. Dr. Oliver Stoeltzing, Head Doctor, Zentrum für Allgemein- und Viszeralchirurgie Riesa-Meißen, Elblandkliniken, Meißen, Germany
Dr Janio Szklaruk, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, United States
Professor Hua Tang, Molecular Biology & Microbiology, School of Basic Medical Sciences, Tianjin Medical University, China Mainland (PRC)
Dr Harrys A Torres, Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, United States
Professor Jia-Sheng Wang, Department of Environmental Health Science, College of Public Health, University of Georgia, United States
Professor Chia Jui Weng, Department of Food Science and Biotechnology, National Chung Hsing University, Taichung, Taiwan
Abstracting and indexing
Journal of Hepatocellular Carcinoma is indexed/tracked/covered by the following services:
Current Contents®/Life Sciences
Directory of Open Access Journals (DOAJ)
EMBASE (Elsevier)
Journal Citation Reports/Science Edition
Pubmed (NLM)
PubMed Central Selective Deposit Medicine & Health (NLM)
Science Citation Index Expanded (Clarivate Analytics)
Scopus (Elsevier)
Open access
Journal of Hepatocellular Carcinoma is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Use our APC finder to calculate your article publishing charge
News, offers and calls for papers
Continuous
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors